Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Safety.
- Registration Number
- NCT00783939
- Lead Sponsor
- Sanofi
- Brief Summary
The purpose of this study is to prove the safety in normal conditions of useof the product Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 31
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Lactic Acid Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
- Primary Outcome Measures
Name Time Method The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction. From the treatment start to the end of the study
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which lactic acid in Dermacyd PH_DETINBACK Tangerine Mix maintains vaginal microbiome homeostasis?
How does the safety profile of lactic acid-based vaginal hygiene products compare to standard-of-care antiseptics in phase 3 trials?
Are there specific biomarkers that correlate with reduced mucosal irritation in lactic acid formulations for feminine hygiene?
What are the potential adverse events associated with lactic acid use in vaginal products and how are they managed clinically?
What are the current combination therapies involving lactic acid for vaginal health and how do they compare to Sanofi's Dermacyd PH_DETINBACK formulation?
Trial Locations
- Locations (1)
Sanofi-Aventis Administrative Office
🇧🇷Sao Paulo, Brazil
Sanofi-Aventis Administrative Office🇧🇷Sao Paulo, Brazil